By A Mystery Man Writer
Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost- Effectiveness Analysis
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook, Molecular Cancer
IJMS, Free Full-Text
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. - Abstract - Europe PMC
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study - ESMO Gastrointestinal Oncology
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
PDF) Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Current Oncology, Free Full-Text
Immunotherapy for head and neck cancer: Present and future - ScienceDirect
Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost- Effectiveness Analysis
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities, Journal of Hematology & Oncology
Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)